RA Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

RA Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-17,899	Closed	-$4.62M	–	100
2021 Q1	$4.62M	Hold	17,899	–	–	0.07%	80
2020 Q4	$3.45M	Sell	17,899 -751	-4%	-$148K	0.05%	80
2020 Q3	$3.79M	Hold	18,650	–	–	0.07%	68
2020 Q2	$5.21M	Sell	18,650 -1,426	-7%	-$390K	0.1%	54
2020 Q1	$6.02M	Buy	20,076 +11,066	+123%	+$3.14M	0.19%	41
2019 Q4	$2.89M	Sell	9,010 -6,927	-43%	-$2.48M	0.09%	34
2019 Q3	$6.08M	Sell	15,937 -12,776	-44%	-$5.06M	0.36%	28
2019 Q2	$12.9M	Buy	+28,713	New	+$14.6M	0.69%	23

Other funds holding XFOR

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

RA Capital Management's XFOR Position: Q2 2021 in Review

RA Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q2 2021, closing a stake of 17,899 shares — an estimated $4.62M sold.

RA Capital Management first reported a position in XFOR in Q2 2019 and held it in 8 quarters. The position peaked at $12.9M in Q2 2019. 62 funds tracked by Wall St. Rank hold XFOR as of Q2 2021.

RA Capital Management reported no remaining X4 Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
RA Capital Management sold 17,899 X4 Pharmaceuticals shares in Q2 2021, an estimated $4.62M.
RA Capital Management first reported a position in X4 Pharmaceuticals in Q2 2019 and held it in 8 quarters.
RA Capital Management's X4 Pharmaceuticals position peaked at $12.9M in Q2 2019.
62 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2021.

Based on RA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.